Buenavista completes the acquisition of Instituto Bernabeu

• The transaction, first announced in December, has now been completed following the relevant regulatory approvals

• Instituto Bernabeu has therefore been integrated with Eugin, a leading assisted reproduction group, to form the second-largest player in this segment in Spain

Madrid, 7 May 2026. Buenavista Equity Partners, a private equity firm specialising in the Spanish low and mid-market segment, today announced the completion of its acquisition of Instituto Bernabeu, following clearance from the relevant competition authorities.

Founded in 1985, Instituto Bernabeu is a leading premium reproductive medicine company, with a presence in Spain and Italy through 10 clinics serving both domestic and international patients. The company generates revenues of more than €30 million and has a strong track record of sustained growth.

Through this transaction, Instituto Bernabeu will combine its capabilities with Eugin to form the second-largest fertility group in Spain and one of the leading players in Europe and Latin America. Together, both companies will have the capacity to treat more than 10,000 patients each year through a network of 52 clinics across nine countries, including six in Europe, such as Spain and Italy, and three in Latin America.

The transaction represents a transformational milestone for Eugin, enabling it to benefit from clear complementarities, including a first-rate management and medical team at the forefront of the sector, as well as economies of scale.